IONIS PHARMACEUTICALS INC (IONS)

Data as of Sep 3, 2026, from SEC Form 4 filings.

XNASPHARMACEUTICAL PREPARATIONSNet insider buying (90d)Watch IONS

See up to 3 months of IONS. The 7-day demo opens the 1M and 3M ranges and puts IONS on your watchlist.

Latest IONS insider trades

Michael R. Hayden - Director
Open-market purchase$801K
Jul 30, 2026
Michael R. Hayden - Director
Open-market purchase

About IONIS PHARMACEUTICALS INC (IONS)

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Headquarters: CARLSBAD, CA
Employees: 1,402
Listed: 1991
Exchange: XNAS
Sector: Health Care

https://www.ionis.com SEC filings for IONS on EDGAR

IONS Form 4 activity by transaction type, last 90 days

Form 4 transaction type	Transactions	Shares	Total value
Open-market purchase	2	20,000	$1.06M
Grant or award	2	6,798
Option exercise	4	20,880

IONS insider transactions (Form 4)

158 Form 4 filings on record, the earliest from Oct 1, 2024, newest first. Filing history page 1 of 3.

Date	Insider	Transaction	Security	Shares	Price	Value
Aug 31, 2026	C. Frank Bennett - Officer	Other	Common Stock	110^{footnote F1}	$51.31	$6K
Footnote F1 (shares): Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027.
Aug 31, 2026	Patrick R. O'Neil - Officer	Other	Common Stock	63^{footnote F1}	$51.31	$3K
Footnote F1 (shares): Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027.
Aug 31, 2026	Brett P. Monia - Officer	Other	Common Stock	98^{footnote F1}	$51.31	$5K
Footnote F1 (shares): Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027.
Aug 31, 2026	Brian Birchler - Officer	Other	Common Stock	58^{footnote F1}	$51.31	$3K
Footnote F1 (shares): Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027.
Jul 30, 2026	Michael R. Hayden - Director	Open-market purchase	Common Stock	15,000	$53.38^{footnote F1}	$801K
Jul 31, 2026	Michael R. Hayden - Director	Open-market purchase	Common Stock	5,000	$51.60^{footnote F3}	$258K
Footnote F1 (price): The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $53.00 to $53.58 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis… Full note on SEC EDGAR Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $51.45 to $51.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis… Full note on SEC EDGAR
Jul 15, 2026	Peter N. Reikes - Director	Grant or award	Restricted Stock Unit	3,399	$0.00	-
Jul 15, 2026	Ludwig Hantson - Director	Grant or award	Restricted Stock Unit	3,399	$0.00	-
Jul 15, 2026	Joan E. Herman - Director	Option exercise	Common Stock	5,220^{footnote F1}	$0.00	-
Jul 15, 2026	Joan E. Herman - Director	Option exercise	Restricted Stock Unit	5,220	$0.00	-
Footnote F1 (shares): Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
Jul 15, 2026	Spencer R. Berthelsen - Director	Option exercise	Common Stock	5,220^{footnote F1}	$0.00	-
Jul 15, 2026	Spencer R. Berthelsen - Director	Option exercise	Restricted Stock Unit	5,220	$0.00	-
Footnote F1 (shares): Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
Jul 7, 2026	C. Frank Bennett - Officer	Open-market sale	Common Stock	5,536^{footnote F1}	$83.58^{footnote F2}	$463K
Jul 7, 2026	C. Frank Bennett - Officer	Other	Common Stock	15,000^{footnote F3}	$0.00	-
Jul 7, 2026	C. Frank Bennett - Officer	Open-market sale	Common Stock	15,000^{footnote F1}	$85.46^{footnote F4}	$1.28M
Jul 7, 2026	C. Frank Bennett - Officer	Other	Restricted Stock Unit	15,000	$0.00	-
Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 31, 2026. Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.070 to $84.065 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis… Full note on SEC EDGAR Footnote F3 (shares): Represents a transfer of 15,000 shares of common stock from direct ownership to indirect ownership held by the Clarence Frank Bennett TTEE Bennett Living Trust Dated 3/12/2008, of which the reporting person is the co-trustee with spouse. Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.015 to $85.730 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis… Full note on SEC EDGAR
Jul 7, 2026	Allene M. Diaz - Director	Option exercise	Common Stock	10,111	$47.11	$476K
Jul 7, 2026	Allene M. Diaz - Director	Option exercise	Non-Qualified Stock Option (right to buy)	10,111	$0.00	-
Jul 7, 2026	Allene M. Diaz - Director	Open-market sale	Common Stock	10,111^{footnote F1}	$85.42^{footnote F2}	$864K
Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.040 to $85.730 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis… Full note on SEC EDGAR
Jul 7, 2026	Holly B. Kordasiewicz - Officer	Open-market sale	Common Stock	362^{footnote F1}	$84.30	$31K
Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2026
Jul 1, 2026	Michael J. Yang - Director	Grant or award	Non-Qualified Stock Option (right to buy)	5,369^{footnote F1}	$0.00	-
Jul 1, 2026	Michael J. Yang - Director	Grant or award	Restricted Stock Unit	2,301^{footnote F1}	$0.00	-
Footnote F1 (shares): Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance… Full note on SEC EDGAR
Jul 1, 2026	Joseph Loscalzo - Director	Grant or award	Non-Qualified Stock Option (right to buy)	5,369^{footnote F1}	$0.00	-
Jul 1, 2026	Joseph Loscalzo - Director	Grant or award	Restricted Stock Unit	2,301^{footnote F1}	$0.00	-
Footnote F1 (shares): Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance… Full note on SEC EDGAR
Jul 1, 2026	Joan E. Herman - Director	Grant or award	Non-Qualified Stock Option (right to buy)	5,369^{footnote F1}	$0.00	-
Jul 1, 2026	Joan E. Herman - Director	Grant or award	Restricted Stock Unit	2,301^{footnote F1}	$0.00	-
Footnote F1 (shares): Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance… Full note on SEC EDGAR
Jul 1, 2026	Joseph Klein III - Director	Option exercise	Common Stock	11,518	$39.94	$460K
Jul 1, 2026	Joseph Klein III - Director	Option exercise	Non-Qualified Stock Option (right to buy)	11,518	$0.00	-
Jul 1, 2026	Joseph Klein III - Director	Open-market sale	Common Stock	99^{footnote F1}	$79.45	$8K
Jul 1, 2026	Joseph Klein III - Director	Open-market sale	Common Stock	11,419^{footnote F1}	$79.04^{footnote F2}	$903K
Jul 1, 2026	Joseph Klein III - Director	Grant or award	Non-Qualified Stock Option (right to buy)	5,369^{footnote F4}	$0.00	-
Jul 1, 2026	Joseph Klein III - Director	Grant or award	Restricted Stock Unit	2,301^{footnote F4}	$0.00	-
Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.39 to $79.38 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals… Full note on SEC EDGAR Footnote F4 (shares): Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance… Full note on SEC EDGAR
Jul 1, 2026	Michael R. Hayden - Director	Grant or award	Non-Qualified Stock Option (right to buy)	5,369^{footnote F1}	$0.00	-
Jul 1, 2026	Michael R. Hayden - Director	Grant or award	Restricted Stock Unit	2,301^{footnote F1}	$0.00	-
Footnote F1 (shares): Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance… Full note on SEC EDGAR
Jul 1, 2026	Allene M. Diaz - Director	Grant or award	Non-Qualified Stock Option (right to buy)	5,369^{footnote F1}	$0.00	-
Jul 1, 2026	Allene M. Diaz - Director	Grant or award	Restricted Stock Unit	2,301^{footnote F1}	$0.00	-
Footnote F1 (shares): Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance… Full note on SEC EDGAR
Jul 1, 2026	Spencer R. Berthelsen - Director	Grant or award	Non-Qualified Stock Option (right to buy)	5,369^{footnote F1}	$0.00	-
Jul 1, 2026	Spencer R. Berthelsen - Director	Grant or award	Restricted Stock Unit	2,301^{footnote F1}	$0.00	-
Footnote F1 (shares): Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance… Full note on SEC EDGAR
Jun 26, 2026	Joseph Baroldi - Officer	Option exercise	Common Stock	3,866	$56.78	$220K
Jun 26, 2026	Joseph Baroldi - Officer	Option exercise	Common Stock	1,769	$32.60	$58K
Jun 26, 2026	Joseph Baroldi - Officer	Open-market sale	Common Stock	5,635^{footnote F1}	$80.16^{footnote F2}	$452K
Jun 26, 2026	Joseph Baroldi - Officer	Option exercise	Non-Qualified Stock Option (right to buy)	1,769	$0.00	-
Jun 26, 2026	Joseph Baroldi - Officer	Option exercise	Non-Qualified Stock Option (right to buy)	3,866	$0.00	-
Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting persons spouse on November 25, 2025. Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.52 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals… Full note on SEC EDGAR
Jun 26, 2026	Patrick R. O'Neil - Officer	Open-market sale	Common Stock	3,069^{footnote F1}	$80.00	$246K
Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025.
Jun 26, 2026	Eugene Schneider - Officer	Option exercise	Common Stock	26,000	$60.89	$1.58M
Jun 26, 2026	Eugene Schneider - Officer	Option exercise	Non-Qualified Stock Option (right to buy)	26,000	$0.00	-
Jun 26, 2026	Eugene Schneider - Officer	Open-market sale	Common Stock	26,000^{footnote F1}	$81.05^{footnote F2}	$2.11M
Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 19, 2025. Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.00 to $81.34 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals… Full note on SEC EDGAR
Jun 24, 2026	Brett P. Monia - Officer	Option exercise	Common Stock	14,565	$32.60	$475K
Jun 25, 2026	Brett P. Monia - Officer	Option exercise	Common Stock	21,072	$32.60	$687K
Jun 26, 2026	Brett P. Monia - Officer	Option exercise	Common Stock	50,000	$56.78	$2.84M
Jun 24, 2026	Brett P. Monia - Officer	Option exercise	Non-Qualified Stock Option (right to buy)	14,565	$0.00	-
Jun 25, 2026	Brett P. Monia - Officer	Option exercise	Non-Qualified Stock Option (right to buy)	21,072	$0.00	-
Jun 26, 2026	Brett P. Monia - Officer	Option exercise	Non-Qualified Stock Option (right to buy)	50,000	$0.00	-
Jun 24, 2026	Brett P. Monia - Officer	Open-market sale	Common Stock	14,565^{footnote F1}	$78.41^{footnote F2}	$1.14M
Jun 25, 2026	Brett P. Monia - Officer	Open-market sale	Common Stock	21,072^{footnote F1}	$78.49^{footnote F3}	$1.65M
Jun 26, 2026	Brett P. Monia - Officer	Open-market sale	Common Stock	50,000^{footnote F1}	$80.59^{footnote F4}	$4.03M
Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025 Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.87 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals… Full note on SEC EDGAR Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.005 to $78.78 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals… Full note on SEC EDGAR Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80 to $81 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc… Full note on SEC EDGAR
Jun 25, 2026	Eric Swayze - Officer	Open-market sale	Common Stock	10,602^{footnote F1}	$79.18^{footnote F2}	$839K
Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 6, 2026. Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.00 to $79.46 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals… Full note on SEC EDGAR
Jun 12, 2026	Holly B. Kordasiewicz - Officer	Option exercise	Common Stock	7,951	$60.89	$484K
Jun 12, 2026	Holly B. Kordasiewicz - Officer	Option exercise	Common Stock	21,000	$60.89	$1.28M
Jun 12, 2026	Holly B. Kordasiewicz - Officer	Option exercise	Common Stock	12,000	$32.60	$391K
Jun 12, 2026	Holly B. Kordasiewicz - Officer	Option exercise	Common Stock	19,895	$56.78	$1.13M
Jun 12, 2026	Holly B. Kordasiewicz - Officer	Option exercise	Non-Qualified Stock Option (right to buy)	12,000	$0.00	-
Jun 12, 2026	Holly B. Kordasiewicz - Officer	Option exercise	Non-Qualified Stock Option (right to buy)	19,895	$0.00	-
Jun 12, 2026	Holly B. Kordasiewicz - Officer	Option exercise	Non-Qualified Stock Option (right to buy)	7,951	$0.00	-
Jun 12, 2026	Holly B. Kordasiewicz - Officer	Option exercise	Non-Qualified Stock Option (right to buy)	21,000	$0.00	-
Jun 12, 2026	Holly B. Kordasiewicz - Officer	Open-market sale	Common Stock	41,004^{footnote F1}	$73.09^{footnote F2}	$3.00M
Jun 12, 2026	Holly B. Kordasiewicz - Officer	Open-market sale	Common Stock	19,842^{footnote F1}	$74.05^{footnote F3}	$1.47M
Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2026 Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.68 to $73.67 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals… Full note on SEC EDGAR Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.735 to $74.28 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals… Full note on SEC EDGAR
Jun 15, 2026	Spencer R. Berthelsen - Director	Option exercise	Common Stock	8,000	$24.42	$195K
Jun 15, 2026	Spencer R. Berthelsen - Director	Option exercise	Non-Qualified Stock Option (right to buy)	8,000	$0.00	-
Jun 15, 2026	Spencer R. Berthelsen - Director	Open-market sale	Common Stock	8,000^{footnote F1}	$73.49	$588K
Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.
Jun 4, 2026	Peter N. Reikes - Director	Grant or award	Non-Qualified Stock Option (right to buy)	10,753	$0.00	-
Jun 4, 2026	Ludwig Hantson - Director	Grant or award	Non-Qualified Stock Option (right to buy)	10,753	$0.00	-
Jun 1, 2026	Spencer R. Berthelsen - Director	Option exercise	Common Stock	8,000	$24.42	$195K
Jun 1, 2026	Spencer R. Berthelsen - Director	Option exercise	Non-Qualified Stock Option (right to buy)	8,000	$0.00	-
Jun 1, 2026	Spencer R. Berthelsen - Director	Open-market sale	Common Stock	8,000^{footnote F1}	$75.67	$605K
Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.
May 13, 2026	Brett P. Monia - Officer	Option exercise	Common Stock	1,316	$32.60	$43K
May 14, 2026	Brett P. Monia - Officer	Option exercise	Common Stock	3,220	$32.60	$105K
May 13, 2026	Brett P. Monia - Officer	Option exercise	Non-Qualified Stock Option (right to buy)	1,316	$0.00	-
May 14, 2026	Brett P. Monia - Officer	Option exercise	Non-Qualified Stock Option (right to buy)	3,220	$0.00	-
May 13, 2026	Brett P. Monia - Officer	Open-market sale	Common Stock	1,316^{footnote F1}	$78.01^{footnote F2}	$103K
May 14, 2026	Brett P. Monia - Officer	Open-market sale	Common Stock	3,220^{footnote F1}	$78.68^{footnote F3}	$253K
Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025 Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.025 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals… Full note on SEC EDGAR Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.075 to $79.01 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals… Full note on SEC EDGAR

Recent IONS Form 8-K filings

Read IONS company news

Sep 23, 2026Item 7.01, 8.01, 9.01

Read the filing on SEC EDGAR

Sep 4, 2026Item 7.01, 8.01, 9.01

Read the filing on SEC EDGAR

Sep 4, 2026Item 7.01, 8.01, 9.01

Read the filing on SEC EDGAR

Jul 29, 2026Item 2.02, 9.01

Recent IONS Form 144 notices of proposed sale

An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.

Filed	Filer	Relationship	Shares	Market value	Notice
Jul 7, 2026	-	-	-	-	View on EDGAR
Jul 7, 2026	-	-	-	-

IONS insider trading FAQ

What is the latest insider trade for IONS?

IONIS PHARMACEUTICALS INC (IONS) had 9 insider filings in the last 90 days, with the most recent on 2026-09-03. The full record for IONS runs to 158 Form 4 filings, the earliest from 2024-10-01. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying IONS stock?

2 insider purchases of IONS were filed in the last 90 days, totaling $1.06M.

How many insiders are selling IONS stock?

No insider sales of IONS were filed in the last 90 days. 175 sales are on record for this company.

Where can I see IONS SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects IONS Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Sep 3, 2026 - C. Frank Bennett view on EDGAR
Sep 3, 2026 - Patrick R. O'Neil view on EDGAR
Sep 3, 2026 - Brett P. Monia view on EDGAR
Sep 3, 2026 - Brian Birchler view on EDGAR
Jul 31, 2026 - Michael R. Hayden view on EDGAR
Jul 17, 2026 - Peter N. Reikes view on EDGAR
Jul 17, 2026 - Ludwig Hantson view on EDGAR
Jul 17, 2026 - Joan E. Herman view on EDGAR
Jul 17, 2026 - Spencer R. Berthelsen view on EDGAR

Related companies with recent insider activity

Learn more

How to read insider buying signals: What an open-market purchase by an insider can and cannot tell you.
Form 144 vs Form 4: A Form 144 announces a planned sale; the Form 4 reports it after it happens.
Insider activity in Health Care: Where IONS's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow IONS with a 7-day demo

IONS on your watchlist
Every IONS Form 4 filing on record
Up to 3 months of IONS price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Form 4 transaction type

Transactions

Total value

Open-market purchase

20,000

$1.06M

Grant or award

6,798

Option exercise

20,880

Date

Insider

Transaction

Security

Price

Value

Aug 31, 2026

C. Frank Bennett - Officer

Other

Common Stock

110^{footnote F1}

$51.31

$6K

Footnote F1 (shares): Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027.

Aug 31, 2026

Patrick R. O'Neil - Officer

Other

Common Stock

63^{footnote F1}

$51.31

$3K

Footnote F1 (shares): Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027.

Aug 31, 2026

Brett P. Monia - Officer

Other

Common Stock

98^{footnote F1}

$51.31

$5K

Footnote F1 (shares): Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027.

Aug 31, 2026

Brian Birchler - Officer

Other

Common Stock

58^{footnote F1}

$51.31

$3K

Footnote F1 (shares): Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027.

Jul 30, 2026

Michael R. Hayden - Director

Open-market purchase

Common Stock

15,000

$53.38^{footnote F1}

$801K

Jul 31, 2026

Michael R. Hayden - Director

Open-market purchase

Common Stock

5,000

$51.60^{footnote F3}

$258K

Footnote F1 (price): The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $53.00 to $53.58 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis… Full note on SEC EDGAR
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $51.45 to $51.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis… Full note on SEC EDGAR

Jul 15, 2026

Peter N. Reikes - Director

Grant or award

Restricted Stock Unit

3,399

$0.00

Jul 15, 2026

Ludwig Hantson - Director

Grant or award

Restricted Stock Unit

3,399

$0.00

Jul 15, 2026

Joan E. Herman - Director

Option exercise

Common Stock

5,220^{footnote F1}

$0.00

Jul 15, 2026

Joan E. Herman - Director

Option exercise

Restricted Stock Unit

5,220

$0.00

Footnote F1 (shares): Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

Jul 15, 2026

Spencer R. Berthelsen - Director

Option exercise

Common Stock

5,220^{footnote F1}

$0.00

Jul 15, 2026

Spencer R. Berthelsen - Director

Option exercise

Restricted Stock Unit

5,220

$0.00

Footnote F1 (shares): Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

Jul 7, 2026

C. Frank Bennett - Officer

Open-market sale

Common Stock

5,536^{footnote F1}

$83.58^{footnote F2}

$463K

Jul 7, 2026

C. Frank Bennett - Officer

Other

Common Stock

15,000^{footnote F3}

$0.00

Jul 7, 2026

C. Frank Bennett - Officer

Open-market sale

Common Stock

15,000^{footnote F1}

$85.46^{footnote F4}

$1.28M

Jul 7, 2026

C. Frank Bennett - Officer

Other

Restricted Stock Unit

15,000

$0.00

Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 31, 2026.
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.070 to $84.065 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis… Full note on SEC EDGAR
Footnote F3 (shares): Represents a transfer of 15,000 shares of common stock from direct ownership to indirect ownership held by the Clarence Frank Bennett TTEE Bennett Living Trust Dated 3/12/2008, of which the reporting person is the co-trustee with spouse.
Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.015 to $85.730 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis… Full note on SEC EDGAR

Jul 7, 2026

Allene M. Diaz - Director

Option exercise

Common Stock

10,111

$47.11

$476K

Jul 7, 2026

Allene M. Diaz - Director

Option exercise

Non-Qualified Stock Option (right to buy)

10,111

$0.00

Jul 7, 2026

Allene M. Diaz - Director

Open-market sale

Common Stock

10,111^{footnote F1}

$85.42^{footnote F2}

$864K

Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025.
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.040 to $85.730 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis… Full note on SEC EDGAR

Jul 7, 2026

Holly B. Kordasiewicz - Officer

Open-market sale

Common Stock

362^{footnote F1}

$84.30

$31K

Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2026

Jul 1, 2026

Michael J. Yang - Director

Grant or award

Non-Qualified Stock Option (right to buy)

5,369^{footnote F1}

$0.00

Jul 1, 2026

Michael J. Yang - Director

Grant or award

Restricted Stock Unit

2,301^{footnote F1}

$0.00

Footnote F1 (shares): Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance… Full note on SEC EDGAR

Jul 1, 2026

Joseph Loscalzo - Director

Grant or award

Non-Qualified Stock Option (right to buy)

5,369^{footnote F1}

$0.00

Jul 1, 2026

Joseph Loscalzo - Director

Grant or award

Restricted Stock Unit

2,301^{footnote F1}

$0.00

Footnote F1 (shares): Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance… Full note on SEC EDGAR

Jul 1, 2026

Joan E. Herman - Director

Grant or award

Non-Qualified Stock Option (right to buy)

5,369^{footnote F1}

$0.00

Jul 1, 2026

Joan E. Herman - Director

Grant or award

Restricted Stock Unit

2,301^{footnote F1}

$0.00

Footnote F1 (shares): Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance… Full note on SEC EDGAR

Jul 1, 2026

Joseph Klein III - Director

Option exercise

Common Stock

11,518

$39.94

$460K

Jul 1, 2026

Joseph Klein III - Director

Option exercise

Non-Qualified Stock Option (right to buy)

11,518

$0.00

Jul 1, 2026

Joseph Klein III - Director

Open-market sale

Common Stock

99^{footnote F1}

$79.45

$8K

Jul 1, 2026

Joseph Klein III - Director

Open-market sale

Common Stock

11,419^{footnote F1}

$79.04^{footnote F2}

$903K

Jul 1, 2026

Joseph Klein III - Director

Grant or award

Non-Qualified Stock Option (right to buy)

5,369^{footnote F4}

$0.00

Jul 1, 2026

Joseph Klein III - Director

Grant or award

Restricted Stock Unit

2,301^{footnote F4}

$0.00

Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025.
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.39 to $79.38 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals… Full note on SEC EDGAR
Footnote F4 (shares): Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance… Full note on SEC EDGAR

Jul 1, 2026

Michael R. Hayden - Director

Grant or award

Non-Qualified Stock Option (right to buy)

5,369^{footnote F1}

$0.00

Jul 1, 2026

Michael R. Hayden - Director

Grant or award

Restricted Stock Unit

2,301^{footnote F1}

$0.00

Footnote F1 (shares): Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance… Full note on SEC EDGAR

Jul 1, 2026

Allene M. Diaz - Director

Grant or award

Non-Qualified Stock Option (right to buy)

5,369^{footnote F1}

$0.00

Jul 1, 2026

Allene M. Diaz - Director

Grant or award

Restricted Stock Unit

2,301^{footnote F1}

$0.00

Footnote F1 (shares): Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance… Full note on SEC EDGAR

Jul 1, 2026

Spencer R. Berthelsen - Director

Grant or award

Non-Qualified Stock Option (right to buy)

5,369^{footnote F1}

$0.00

Jul 1, 2026

Spencer R. Berthelsen - Director

Grant or award

Restricted Stock Unit

2,301^{footnote F1}

$0.00

Footnote F1 (shares): Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance… Full note on SEC EDGAR

Jun 26, 2026

Joseph Baroldi - Officer

Option exercise

Common Stock

3,866

$56.78

$220K

Jun 26, 2026

Joseph Baroldi - Officer

Option exercise

Common Stock

1,769

$32.60

$58K

Jun 26, 2026

Joseph Baroldi - Officer

Open-market sale

Common Stock

5,635^{footnote F1}

$80.16^{footnote F2}

$452K

Jun 26, 2026

Joseph Baroldi - Officer

Option exercise

Non-Qualified Stock Option (right to buy)

1,769

$0.00

Jun 26, 2026

Joseph Baroldi - Officer

Option exercise

Non-Qualified Stock Option (right to buy)

3,866

$0.00

Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting persons spouse on November 25, 2025.
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.52 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals… Full note on SEC EDGAR

Jun 26, 2026

Patrick R. O'Neil - Officer

Open-market sale

Common Stock

3,069^{footnote F1}

$80.00

$246K

Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025.

Jun 26, 2026

Eugene Schneider - Officer

Option exercise

Common Stock

26,000

$60.89

$1.58M

Jun 26, 2026

Eugene Schneider - Officer

Option exercise

Non-Qualified Stock Option (right to buy)

26,000

$0.00

Jun 26, 2026

Eugene Schneider - Officer

Open-market sale

Common Stock

26,000^{footnote F1}

$81.05^{footnote F2}

$2.11M

Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 19, 2025.
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.00 to $81.34 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals… Full note on SEC EDGAR

Jun 24, 2026

Brett P. Monia - Officer

Option exercise

Common Stock

14,565

$32.60

$475K

Jun 25, 2026

Brett P. Monia - Officer

Option exercise

Common Stock

21,072

$32.60

$687K

Jun 26, 2026

Brett P. Monia - Officer

Option exercise

Common Stock

50,000

$56.78

$2.84M

Jun 24, 2026

Brett P. Monia - Officer

Option exercise

Non-Qualified Stock Option (right to buy)

14,565

$0.00

Jun 25, 2026

Brett P. Monia - Officer

Option exercise

Non-Qualified Stock Option (right to buy)

21,072

$0.00

Jun 26, 2026

Brett P. Monia - Officer

Option exercise

Non-Qualified Stock Option (right to buy)

50,000

$0.00

Jun 24, 2026

Brett P. Monia - Officer

Open-market sale

Common Stock

14,565^{footnote F1}

$78.41^{footnote F2}

$1.14M

Jun 25, 2026

Brett P. Monia - Officer

Open-market sale

Common Stock

21,072^{footnote F1}

$78.49^{footnote F3}

$1.65M

Jun 26, 2026

Brett P. Monia - Officer

Open-market sale

Common Stock

50,000^{footnote F1}

$80.59^{footnote F4}

$4.03M

Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.87 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals… Full note on SEC EDGAR
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.005 to $78.78 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals… Full note on SEC EDGAR
Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80 to $81 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc… Full note on SEC EDGAR

Jun 25, 2026

Eric Swayze - Officer

Open-market sale

Common Stock

10,602^{footnote F1}

$79.18^{footnote F2}

$839K

Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 6, 2026.
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.00 to $79.46 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals… Full note on SEC EDGAR

Jun 12, 2026

Holly B. Kordasiewicz - Officer

Option exercise

Common Stock

7,951

$60.89

$484K

Jun 12, 2026

Holly B. Kordasiewicz - Officer

Option exercise

Common Stock

21,000

$60.89

$1.28M

Jun 12, 2026

Holly B. Kordasiewicz - Officer

Option exercise

Common Stock

12,000

$32.60

$391K

Jun 12, 2026

Holly B. Kordasiewicz - Officer

Option exercise

Common Stock

19,895

$56.78

$1.13M

Jun 12, 2026

Holly B. Kordasiewicz - Officer

Option exercise

Non-Qualified Stock Option (right to buy)

12,000

$0.00

Jun 12, 2026

Holly B. Kordasiewicz - Officer

Option exercise

Non-Qualified Stock Option (right to buy)

19,895

$0.00

Jun 12, 2026

Holly B. Kordasiewicz - Officer

Option exercise

Non-Qualified Stock Option (right to buy)

7,951

$0.00

Jun 12, 2026

Holly B. Kordasiewicz - Officer

Option exercise

Non-Qualified Stock Option (right to buy)

21,000

$0.00

Jun 12, 2026

Holly B. Kordasiewicz - Officer

Open-market sale

Common Stock

41,004^{footnote F1}

$73.09^{footnote F2}

$3.00M

Jun 12, 2026

Holly B. Kordasiewicz - Officer

Open-market sale

Common Stock

19,842^{footnote F1}

$74.05^{footnote F3}

$1.47M

Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2026
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.68 to $73.67 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals… Full note on SEC EDGAR
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.735 to $74.28 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals… Full note on SEC EDGAR

Jun 15, 2026

Spencer R. Berthelsen - Director

Option exercise

Common Stock

8,000

$24.42

$195K

Jun 15, 2026

Spencer R. Berthelsen - Director

Option exercise

Non-Qualified Stock Option (right to buy)

8,000

$0.00

Jun 15, 2026

Spencer R. Berthelsen - Director

Open-market sale

Common Stock

8,000^{footnote F1}

$73.49

$588K

Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.

Jun 4, 2026

Peter N. Reikes - Director

Grant or award

Non-Qualified Stock Option (right to buy)

10,753

$0.00

Jun 4, 2026

Ludwig Hantson - Director

Grant or award

Non-Qualified Stock Option (right to buy)

10,753

$0.00

Jun 1, 2026

Spencer R. Berthelsen - Director

Option exercise

Common Stock

8,000

$24.42

$195K

Jun 1, 2026

Spencer R. Berthelsen - Director

Option exercise

Non-Qualified Stock Option (right to buy)

8,000

$0.00

Jun 1, 2026

Spencer R. Berthelsen - Director

Open-market sale

Common Stock

8,000^{footnote F1}

$75.67

$605K

Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.

May 13, 2026

Brett P. Monia - Officer

Option exercise

Common Stock

1,316

$32.60

$43K

May 14, 2026

Brett P. Monia - Officer

Option exercise

Common Stock

3,220

$32.60

$105K

May 13, 2026

Brett P. Monia - Officer

Option exercise

Non-Qualified Stock Option (right to buy)

1,316

$0.00

May 14, 2026

Brett P. Monia - Officer

Option exercise

Non-Qualified Stock Option (right to buy)

3,220

$0.00

May 13, 2026

Brett P. Monia - Officer

Open-market sale

Common Stock

1,316^{footnote F1}

$78.01^{footnote F2}

$103K

May 14, 2026

Brett P. Monia - Officer

Open-market sale

Common Stock

3,220^{footnote F1}

$78.68^{footnote F3}

$253K

Footnote F1 (shares): Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.025 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals… Full note on SEC EDGAR
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.075 to $79.01 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals… Full note on SEC EDGAR

Filed

Filer

Relationship

Market value

Notice

Jul 7, 2026

View on EDGAR

Jul 7, 2026